CD274 and head and neck squamous cell carcinoma: Importantly, PD-L2 status was shown to predict clinical response to pembrolizumab independently of PD-L1 expression in 172 patients with HNSCC, though evaluation of PD-L2 is not regularly employed when considering ICI candidacy [41].